{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T01:54:03Z","timestamp":1776995643686,"version":"3.51.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:00:00Z","timestamp":1615507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10157-021-02028-5","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T13:19:43Z","timestamp":1615555183000},"page":"788-801","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy and safety of mycophenolate mofetil in the\u00a0treatment for IgA nephropathy: a meta-analysis of randomized controlled trials"],"prefix":"10.1007","volume":"25","author":[{"given":"Xiao-Jie","family":"Peng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Min","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei-Hui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan-Shan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunhui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,12]]},"reference":[{"issue":"245","key":"2028_CR1","first-page":"709","volume":"64","author":"G D\u2019Amico","year":"1987","unstructured":"D\u2019Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64(245):709\u201327.","journal-title":"Q J Med"},{"issue":"25","key":"2028_CR2","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402\u201314.","journal-title":"N Engl J Med"},{"issue":"10","key":"2028_CR3","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1681\/ASN.2011030221","volume":"22","author":"J Floege","year":"2011","unstructured":"Floege J, Eitner F. Current therapy for IgA nephropathy. J Am Soc Nephrol. 2011;22(10):1785\u201394.","journal-title":"J Am Soc Nephrol"},{"issue":"1 Pt 2","key":"2028_CR4","first-page":"77","volume":"10","author":"AC Allison","year":"1996","unstructured":"Allison AC, Eugui EM. Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant. 1996;10(1 Pt 2):77\u201384.","journal-title":"Clin Transplant"},{"issue":"2\u20133","key":"2028_CR5","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM. Mycophenolate mofetil and its mechanism of action. Immunopharmacology. 2000;47(2\u20133):85\u2013118.","journal-title":"Immunopharmacology"},{"key":"2028_CR6","doi-asserted-by":"crossref","unstructured":"Choi MJ, Eustace JA, Gimenez LF et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int. 2002;61(3):1098\u2013114.","DOI":"10.1046\/j.1523-1755.2002.00214.x"},{"key":"2028_CR7","doi-asserted-by":"crossref","unstructured":"Tang S, Leung JC, Chan LY et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. 2005;68(2):802\u201312","DOI":"10.1111\/j.1523-1755.2005.00460.x"},{"issue":"6","key":"2028_CR8","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/ki.2009.499","volume":"77","author":"SC Tang","year":"2010","unstructured":"Tang SC, Tang AW, Wong SS, Leung JC, Ho YW, Lai KN. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int. 2010;77(6):543\u20139.","journal-title":"Kidney Int"},{"key":"2028_CR9","doi-asserted-by":"crossref","unstructured":"Maes BD, Oyen R Claes K et a1. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int. 2004;65:1842\u20139","DOI":"10.1111\/j.1523-1755.2004.00588.x"},{"key":"2028_CR10","doi-asserted-by":"crossref","unstructured":"Frisch G, Lin J, Rosenstock J, Markowitz G et a1. Mycophenolate mofetil (MMF) vs. placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant. 2005;20:2139\u201345","DOI":"10.1093\/ndt\/gfh974"},{"key":"2028_CR11","unstructured":"Higgins JPT, Green S (eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. https:\/\/www.cochrane-handbook.org. Accessed 13 Nov 2012."},{"key":"2028_CR12","doi-asserted-by":"crossref","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG.Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2028_CR13","doi-asserted-by":"crossref","unstructured":"Deeks JJ.Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ.2001; 323(7305):157\u201362.","DOI":"10.1136\/bmj.323.7305.157"},{"key":"2028_CR14","unstructured":"Chen X, Chen P, Cai G, Wu J, Cui Y, Zhang Y, Liu S, Tang L. A\u00a0randomized\u00a0control\u00a0trial\u00a0of\u00a0mycophenolate mofeil\u00a0treatment\u00a0in\u00a0severe\u00a0IgA nephropathy. Zhonghua Yi Xue Za Zhi. 2002;82(12):796\u2013801"},{"issue":"6","key":"2028_CR15","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","volume":"69","author":"JH Hou","year":"2017","unstructured":"Hou JH, Le WB, Chen N, Wang WM, Liu ZS, Liu D, Chen JH, Tian J, Fu P, Hu ZX, Zeng CH, Liang SS, Zhou ML, Zhang HT, Liu ZH. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis. 2017;69(6):788\u201395.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2028_CR16","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","volume":"66","author":"RJ Hogg","year":"2015","unstructured":"Hogg RJ, Bay RC, Jennette JC, Sibley R, Kumar S, Fervenza FC, Appel G, Cattran D, Fischer D, Hurley RM. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis. 2015;66(5):783\u201391.","journal-title":"Am J Kidney Dis"},{"key":"2028_CR17","unstructured":"Yu X, Liao W, Huang L, Hao L et al. A prospective, multicenter, randomized controlled trial of mycophenolate mofetil (MMF) in patients with IgA nephropathy. In: Proceedings of the third annual meeting of Chinese nephrology physicians, Guangzhou. 2010;229\u201330."},{"key":"2028_CR18","first-page":"34","volume-title":"Clinical and Experimental Study of Immunosuppressive Agents for IgA Nephropathy[D]","author":"H Liu","year":"2010","unstructured":"Liu H. Clinical and Experimental Study of Immunosuppressive Agents for IgA Nephropathy[D]. Shang Hai: Fudan University; 2010. p. 34\u201346."},{"key":"2028_CR19","first-page":"34","volume-title":"Clinical study of glucocorticoid combined with immunosuppressant in the treatment of IgA nephropathy patients with impaired renal function[D]","author":"H Li","year":"2015","unstructured":"Li H. Clinical study of glucocorticoid combined with immunosuppressant in the treatment of IgA nephropathy patients with impaired renal function[D]. Shang Hai: Shanghai Jiao Tong University; 2015. p. 34\u201346."},{"key":"2028_CR20","unstructured":"Yong-qiang, L. Clinical study of prednisone and mycophenolate mofetil in treatment of IgA mesangial proliferative glomerulonephrifis. Chin J Postgrad Med.2013;36(34):17\u20139 (in Chinese)."},{"issue":"3","key":"2028_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1053\/ajkd.2002.31399","volume":"39","author":"O Hotta","year":"2002","unstructured":"Hotta O, Furuta T, Chiba S, Tomioka S, Taguma Y. Regression of IgA nephropathy: a repeat biopsy study. Am J Kidney Dis. 2002;39(3):493\u2013502.","journal-title":"Am J Kidney Dis"},{"issue":"7","key":"2028_CR22","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1007\/s00108-018-0443-0","volume":"59","author":"R Bollin","year":"2018","unstructured":"Bollin R, Haller H. Pathophysiology and treatment of IgA nephropathy. Internist (Berl). 2018;59(7):736\u201340.","journal-title":"Internist (Berl)."},{"issue":"2","key":"2028_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/ajkd.2000.8966","volume":"36","author":"G D\u2019Amico","year":"2000","unstructured":"D\u2019Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36(2):227\u201337.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2028_CR24","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1681\/ASN.2011111112","volume":"23","author":"J Lv","year":"2012","unstructured":"Lv J, Xu D, Perkovic V, Ma X, Johnson DW, Woodward M, Levin A, Zhang H, Wang H. TESTING Study Group. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol. 2012;23(6):1108\u201316.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2028_CR25","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1517\/14656566.2015.1038238","volume":"16","author":"L Tian","year":"2015","unstructured":"Tian L, Shao X, Xie Y, Wang L, Wang Q, Che X, Ni Z, Mou S. The long-term efficacy and safety of immunosuppressive therapy on the progression of IgA nephropathy: a meta-analysis of controlled clinical trials with more than 5-year follow-up. Expert Opin Pharmacother. 2015;16(8):1137\u201347.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"2028_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40620-014-0165-x","volume":"28","author":"XH Shen","year":"2015","unstructured":"Shen XH, Liang SS, Chen HM, Le WB, Jiang S, Zeng CH, Zhou ML, Zhang HT, Liu ZH. Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation. J Nephrol. 2015;28(4):441\u20139.","journal-title":"J Nephrol"},{"key":"2028_CR27","doi-asserted-by":"crossref","unstructured":"Dooley MA, Jayne D, Ginzler EM, Isenberg D,\u00a0Olsen NJ,\u00a0Wofsy D,\u00a0Eitner F,\u00a0Appel GB,\u00a0Contreras G,\u00a0Lisk L,\u00a0Solomons N;\u00a0ALMS Group. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011; 365(20):1886\u201395.","DOI":"10.1056\/NEJMoa1014460"},{"key":"2028_CR28","doi-asserted-by":"publisher","unstructured":"Beckwith H, Medjeral-Thomas N,\u00a0Galliford J,\u00a0Griffith M,\u00a0Levy J,\u00a0Lightstone L, Palmer A,\u00a0Roufosse C,\u00a0Pusey C,\u00a0Cook HT, Cairns T. Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment. Nephrol Dial Transplant. 2017;32 (suppl_1):i123\u2013i128. https:\/\/doi.org\/10.1093\/ndt\/gfw326.","DOI":"10.1093\/ndt\/gfw326"},{"key":"2028_CR29","doi-asserted-by":"crossref","unstructured":"Sandsmark DK,\u00a0Mess\u00e9 SR,\u00a0Zhang X,\u00a0Roy J,\u00a0Nessel L,\u00a0Lee Hamm L,\u00a0He J,\u00a0Horwitz EJ,\u00a0Jaar BG,\u00a0Kallem RR,\u00a0Kusek JW,\u00a0Mohler ER 3rd,\u00a0Porter A,\u00a0Seliger SL,\u00a0Sozio SM,Townsend RR,\u00a0Feldman HI,\u00a0Kasner SE;\u00a0CRIC Study Investigators. Proteinuria, but not eGFR, predicts\u00a0stroke\u00a0risk in chronic kidney disease: chronic renal insufficiency cohort study. Stroke .2015;46(8):2075\u20132080.","DOI":"10.1161\/STROKEAHA.115.009861"},{"issue":"3","key":"2028_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2215\/CJN.04820511","volume":"7","author":"JK Kim","year":"2012","unstructured":"Kim JK, Kim JH, Lee SC, Kang EW, Chang TI, Moon SJ, Yoon SY, Yoo TH, Kang SW, Choi KH, Han DS, Kie JH, Lim BJ, Jeong HJ, Han SH. Clinical features and outcomes of IgA nephropathy with nephrotic syndrome. Clin J Am Soc Nephrol. 2012;7(3):427\u201336.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2028_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.5301\/JN.2011.8452","volume":"25","author":"D Roccatello","year":"2012","unstructured":"Roccatello D, Rossi D, Marletto F, Naretto C, Sciascia S, Baldovino S, Piras D, Giachino O. Long-term effects of methylprednisolone pulses and mycophenolate mofetil in IgA nephropathy patients at risk of progression. J Nephrol. 2012;25(2):198\u2013203.","journal-title":"J Nephrol"},{"key":"2028_CR32","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1093\/ndt\/gft219","volume":"29","author":"Q Wan","year":"2014","unstructured":"Wan Q, Hu H, He Y, Li T. Is mycophenolate mofetil combined with low-dose prednisone an effective therapeutic option for Chinese patients with lee class III, IV, V IgA nephropathy? Nephrol Dial Transplant. 2014;29:442\u20133.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2028_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.kjms.2014.10.004","volume":"31","author":"QJ Wan","year":"2015","unstructured":"Wan QJ, Hu HF, He YC, Luan SD, Chen HT, Liu HP, Li T, Xu Y, Xu HL, Liao Y. Severe pneumonia in mycophenolate mofetil combined with low-dose corticosteroids-treated patients with immunoglobulin A nephropathy. Kaohsiung J Med Sci. 2015;31(1):42\u20136.","journal-title":"Kaohsiung J Med Sci"},{"issue":"23","key":"2028_CR34","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, Panzer U, Peters H, Benck U, Mertens PR, Kuhlmann U. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225\u201336.","journal-title":"N Engl J Med"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-021-02028-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-021-02028-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-021-02028-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T16:06:35Z","timestamp":1622045195000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-021-02028-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["2028"],"URL":"https:\/\/doi.org\/10.1007\/s10157-021-02028-5","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"23 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict of interest exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}